Recent Posts on This Topic | See All >
[Source: The Arizona Republic] - A Mesa-based company that markets a drug-analysis technology has completed its first examination of an investigational cancer drug being developed by a Canadian biotechnology company.
Predictive Biomarker Sciences, a for-profit company partly owned by Phoenix-based Translational Genomics Research Institute, analyzed a drug candidate being developed by Ottawa, Ontario-based PharmaGap. The analysis suggested that PharmaGap's potential drug, called GAP-107B8, attacks the membrane of colon cancer cells while having less impact on non-cancerous cells.
For more information: Mesa-based Predictive Biomarker Sciences tests cancer drug
Now available: “Arizona’s Bioscience Roadmap 2014-2025: Advancing the Biosciences and Improving Health Outcomes,” is now available along with its supplement, “Summary of Goals, Strategies, and Potential Actions.” An overview by Walter Plosila, Ph.D., Battelle senior advisor, is also available. The updated Roadmap provides a long-term strategy for Arizona to achieve bioscience success over the next decade.